Posted by Michael Wonder on 02 Aug 2022
Marius Pharmaceuticals receives FDA approval of Kyzatrex, an oral testosterone replacement therapy
2 August 2022 - Marius Pharmaceuticals today announced the approval of Kyzatrex (testosterone undecanoate) by the U.S. FDA.
Kyzatrex is an oral testosterone replacement therapy indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.
Kyzarex is a proprietary oral softgel capsule that is absorbed primarily via the lymphatic system, avoiding liver toxicity.
